Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis

Hepatology Research

Volumn 44, Issue 7, 2014, Pages 769-778

  Eiró, Noemí ^a   Altadill, Antonio ^a   Juárez, Luis M ^a   Rodríguez, Manuel ^b   González, Luis O ^a   Atienza, Sara ^a   Bermúdez, Sandra ^a   Fernandez Garcia, Belen ^a   Fresno Forcelledo, Manuel F ^b   Rodrigo, Luis ^b   Vizoso, Francisco J ^a  

^a Research Unit Foundation Hospital of Jove   (Spain)

^b Asturias University Hospital   (Spain)

Author keywords

Hepatocellular carcinoma; Immunology of cancer; Overall survival; Stromal cells; Toll like receptors; Tumor aggressiveness

Indexed keywords

TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84903880557     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12180     Document Type: Article

References (45)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
3. Marin JJ, Romero MR, Martinez-Becerra P, Herraez E, Briz O. Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. Curr Mol Med 2009; 9: 1108-1129.
4. Heidland A, Klassen A, Rutkowski P, Bahner U. The contribution of Rudolf Virchow to the concept of inflammation: what is still of importance? J Nephrol 2006; 19 (Suppl 10): S102-109.
5. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
6. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13: 816-825.
7. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
8. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005; 26: 469-476.
9. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-335.
10. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009; 61: 177-197.
11. Fukata M, Chen A, Vamadevan AS etal. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007; 133: 1869-1881.
12. Swann JB, Vesely MD, Silva A etal. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A 2008; 105: 652-656.
13. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005; 28: 886-892.
14. Seki E, De Minicis S, Osterreicher CH etal. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332.
15. Dapito DH, Mencin A, Gwak GY etal. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-516.
16. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
18. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993; 67: 773-775.
19. Vizoso FJ, Gonzalez LO, Corte MD etal. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007; 96: 903-911.
20. Altadill A, Rodriguez M, Gonzalez LO etal. Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. Dig Liver Dis 2009; 41: 740-748.
21. Eiro N, Gonzalez L, Gonzalez LO etal. Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol 2012; 32: 848-854.
22. Eiro N, Gonzalez LO, Atienza S etal. Prediction of metastatic breast cancer in non-sentinel lymph nodes based on metalloprotease-1 expression by the sentinel lymph node. Eur J Cancer 2013; 49: 1009-1017.
23. Shi SR, Liu C, Balgley BM, Lee C, Taylor CR. Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J Histochem Cytochem 2006; 54: 739-743.
24. Altadill A, Eiro N, Gonzalez LO etal. Comparative analysis of the expression of metalloproteases and their inhibitors in resected crohn's disease and complicated diverticular disease. Inflamm Bowel Dis 2012; 18: 120-130.
25. De Creus A, Abe M, Lau AH, Hackstein H, Raimondi G, Thomson AW. Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin. J Immunol 2005; 174: 2037-2045.
26. Lichtman SN, Wang J, Lemasters JJ. LPS receptor CD14 participates in release of TNF-alpha in RAW 264.7 and peritoneal cells but not in kupffer cells. Am J Physiol 1998; 275: G39-46.
27. van Egmond M, van Garderen E, van Spriel AB etal. FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 2000; 6: 680-685.
28. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168: 554-561.
29. Machida K, Tsukamoto H, Mkrtchyan H etal. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A 2009; 106: 1548-1553.
30. Maeda S. NF-kappaB, JNK, and TLR signaling pathways in hepatocarcinogenesis. Gastroenterol Res Pract 2010; 2010: 367694.
31. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009; 58: 704-720.
32. CLIP TCotLIPI Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000; 31: 840-845.
33. Huo TI, Hsu CY, Huang YH etal. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol 2010; 10: 146.
34. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
35. Allhorn S, Boing C, Koch AA, Kimmig R. Gashaw I TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol 2008; 6: 40.
36. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO etal. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 2011; 60: 217-226.
37. Gonzalez-Reyes S, Marin L, Gonzalez L etal. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010; 10: 665.
38. Morikawa T, Sugiyama A, Kume H etal. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 2007; 13: 5703-5709.
39. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC etal. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 2009; 69: 7329-7337.
40. Yoneda K, Sugimoto K, Shiraki K etal. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol 2008; 33: 929-936.
41. Tanaka J, Sugimoto K, Shiraki K etal. Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int J Oncol 2010; 37: 805-814.
42. Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol 2009; 24: 943-954.
43. Larmonier CB, Arnould L, Larmonier N etal. Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer. Int J Mol Med 2004; 13: 355-361.
44. Tamura R, Kanda T, Imazeki F etal. Hepatitis C Virus nonstructural 5A protein inhibits lipopolysaccharide-mediated apoptosis of hepatocytes by decreasing expression of Toll-like receptor 4. J Infect Dis 2011; 204: 793-801.
45. Taylor KE, Mossman KL. Recent advances in understanding viral evasion of type I interferon. Immunology 2013; 138: 190-197.